Nephrology News
Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects
1.
Ahlenstiel-Grunow T, Kanzelmeyer NK, Froede K, Kreuzer M, Drube Lerch C, Pape L (2017) Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study. Pediatr Nephrol 32:91–97CrossRefPubMedGoogle Scholar
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/